» Articles » PMID: 15230936

Antiretroviral Therapy and Health Care Utilization: a Study of Privately Insured Men and Women with HIV Disease

Overview
Journal Health Serv Res
Specialty Health Services
Date 2004 Jul 3
PMID 15230936
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compare the use of antiretroviral therapy and other health care resources by women and men with HIV disease who are privately insured.

Data Sources: Data were obtained from the MarketScan Commercial Claims and Encounter Database produced by the Medstat Group, Inc., of Ann Arbor, Michigan. This database includes eligibility files as well as claims data for inpatient care, outpatient care, physician services, and prescription drugs for enrollees in employer-sponsored benefit plans for 24 large employers around the nation.

Study Design: Examine utilization by 2,026 privately insured persons (1,494 men and 532 women) with HIV disease in calendar year 2000 under the age of 65.

Principal Findings: Using a simple comparison, we found that 71 percent of men (68.7 to 73.3 percent is 95 percent confidence interval) and 39 percent of women (35.1 to 43.5 percent is 95 percent confidence interval) with HIV disease received antiretroviral therapy. We also found that the average annual drug cost was $9,037 for a man ($8,372 to $9,702 is 95 percent confidence interval) and $3,893 for a woman ($3,476 to $4,490 is 95 percent confidence interval). Furthermore, we found that the out-of-pocket expenses comprised 10 percent of total expenses for men ($1,617 out of $16,405) and 4 percent for women ($405 out of $10,397).

Conclusion: There are major differences in the utilization and cost of health care between privately insured men and women with HIV disease.

Citing Articles

Detection of Patient HIV-1 Drug Resistance Mutations in Russia's Northwestern Federal District in Patients with Treatment Failure.

Shchemelev A, Ostankova Y, Zueva E, Semenov A, Totolian A Diagnostics (Basel). 2022; 12(8).

PMID: 36010172 PMC: 9406370. DOI: 10.3390/diagnostics12081821.


Sex differences in benzodiazepine use in the HIV-infected population.

Wixson S, Brouwer E AIDS Care. 2014; 26(10):1218-22.

PMID: 24625199 PMC: 4087069. DOI: 10.1080/09540121.2014.894615.


Economic models of antiretroviral therapy: searching for the optimal strategy.

Hellinger F Pharmacoeconomics. 2006; 24(7):631-42.

PMID: 16802839 DOI: 10.2165/00019053-200624070-00002.

References
1.
Bozzette S, Berry S, Duan N, Frankel M, Leibowitz A, Lefkowitz D . The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 1998; 339(26):1897-904. DOI: 10.1056/NEJM199812243392606. View

2.
Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View

3.
Shapiro M, Morton S, McCaffrey D, Senterfitt J, Fleishman J, Perlman J . Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999; 281(24):2305-15. DOI: 10.1001/jama.281.24.2305. View

4.
Bozzette S, Joyce G, McCaffrey D, Leibowitz A, Morton S, Berry S . Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001; 344(11):817-23. DOI: 10.1056/NEJM200103153441107. View

5.
Tobin J, Wassertheil-Smoller S, WEXLER J, Steingart R, Budner N, Lense L . Sex bias in considering coronary bypass surgery. Ann Intern Med. 1987; 107(1):19-25. DOI: 10.7326/0003-4819-107-1-19. View